NCT05960851

A Study of LY3871801 in Healthy Asian and Non-Asian Participants

A Phase I, Participant- and Investigator-Blind, Single-center Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of LY3871801 in Healthy Asian and Non-Asian Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3871801 when administered as multiple doses in Healthy Asian and Non-Asian Participants. The study will also evaluate the amount of LY3871801 that gets into the blood stream and how long it takes the body to get rid of it in these participants. The study will be conducted in two parts (A \& B). The study will last up to approximately 24 days excluding the screening period.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LY3871801	Administered orally.
DRUG	Placebo	Administered orally.

Timeline

• Start date: 2023-08-09
• Primary completion: 2023-10-25
• Completion: 2023-10-25
• First posted: 2023-07-27
• Last updated: 2024-01-10

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study